Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Rad Laboratories reports robust earnings, eyes growth through new products

Bio-Rad Laboratories showcased strong financial performance, operational improvements, and strategic initiatives during the Q4 2022 earnings call. Despite challenges like supply chain disruptions and margin impacts, the company remains optimistic about its growth prospects and commitment to long-term targets.

Bio-Rad reports resilient Q1 performance amidst challenges and opportunities

Bio-Rad Laboratories navigated challenges in Q1 2023 to achieve core sales growth and solid non-GAAP net income, with a revised 2023 outlook projecting 4.5% revenue growth.
The impact of Russian sanctions and margin improvement plans were key discussion points, alongside the company's focus on expense management and operational transformation.
With a strategic approach to growth, strong performance in key business segments, and a focus on operational efficiency, Bio-Rad aims to capitalize on opportunities for expansion and resilience.

Bio-Rad reports Q2 earnings decline, eyes ddPCR growth opportunities

Bio-Rad Laboratories faced challenges in BioPharma but showed strengths in Clinical Diagnostics and Life Science segments.
Despite a decline in net sales, the company reported strong demand for ddPCR and authorized a new share repurchase program.
Anticipated challenges in BioPharma and China may impact revenue growth, but opportunities exist in expanding ddPCR sales and cost-saving measures.
The company maintains a strong cash position, views its valuation favorably, and plans to participate in upcoming healthcare conferences.

Bio-Rad Labs faces Q3 challenges, eyes ddPCR market growth

Bio-Rad Laboratories faced challenges in Q3 2023 due to biopharma segment issues and economic constraints in China, impacting revenue and forecasting.
Despite weaknesses, the company saw growth in Clinical Diagnostics revenue and remains focused on operational transformation and strategy execution.
Analysts raised concerns about market dynamics and share losses, while Bio-Rad plans to address challenges and capitalize on opportunities in the ddPCR market.
The company anticipates a strong Q4 to offset Q3 challenges and is prepared for potential macroeconomic impacts on biotechnology spending.

Bio-Rad Labs reports Q4 revenue decline, eyes growth opportunities

Bio-Rad Laboratories navigated challenges in Q4 2023, with revenue declines but operational resilience in key segments.
The company faces headwinds in the China market but sees opportunities in new product launches and market recovery.
Financial stability is evident with strong cash reserves, while strategic adjustments are needed to drive future growth.
Guidance for 2024 hints at a potential turnaround, with a focus on operational efficiency and revenue expansion.

Bio-Rad Laboratories reports mixed Q1 performance, maintains outlook optimism

Bio-Rad Laboratories' Q1 2024 earnings call highlighted a mixed performance with declines in Life Science sales but growth in Clinical Diagnostics. Despite challenges in certain segments, the company maintains its full-year outlook and is optimistic about long-term growth strategies and market trends.

Bio-Rad Laboratories reports solid Q2 performance amidst global spending constraints

Bio-Rad Laboratories had a solid quarter but revised full-year outlook due to global spending constraints.
Operational improvements and successful share repurchases demonstrate resilience and strategic focus.
Challenges in the Life Science group highlight areas for improvement and strategic decision-making.

Bio-Rad Laboratories exceeds revenue targets in Q3 2024 earnings call

Bio-Rad Laboratories reported a strong Q3 performance with revenue surpassing targets driven by product mix and cost efficiencies.
While facing challenges in certain segments, opportunities lie in the expected return to growth in 2025 and the expansion of the Droplet Digital PCR franchise.
Maintained revenue guidance for 2024 with margin improvements and a focus on corporate transformations and acquisitions for future growth.
Analyst questions during the call covered a range of topics including margins, market dynamics, and product pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Investors are optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies in the second quarter and raised 2021 guidance.

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.

Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q2 2021 Results - Earnings Call Transcript

Bio-Rad (BIO) delivered earnings and revenue surprises of 86.32% and 17.29%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Q2 Earnings and Revenues Beat Estimates

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2021. Second-quarter 2021 net sales were $715.9 million, an increase of 33.4 percent compared to $536.9 million reported for the second quarter of 2020. On a currency-neutral basis, quarterly sales increased 27.5 percent compared to the same period in 2020. Second-qua

Bio-Rad Reports Second-Quarter 2021 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Bio-Rad and 10x Genomics, Inc. (Nasdaq: TXG) have reached a final settlement to resolve multiple long-running litigations in Massachusetts, Delaware, California, Germany, and before the International Trade Commission. The settlement includes a global patent cross-license for patents held by both Bio-Rad and 10x Genomi

Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations

Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?

Rite Aid

The stock price of Bio-Rad Laboratories, a life science research and clinical diagnostic products company, has seen a 10% rise over the last twenty-one trading days, while it is up 30% over the last year, driven by positive developments for the company. Last month, Bio-Rad announced its partnership.

What's Next For Bio-Rad Laboratories Stock After A 10% Rise In A Month?

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2021 on Thursday, July 29, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day. To listen, call 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., passcode: 5382265.

Bio-Rad to Report Second-Quarter 2021 Financial Results, Thursday, July 29, 2021

Bio-Rad (BIO) and Seegene team up to develop and commercialize molecular diagnostic products in the United States.

Bio-Rad (BIO)-Seegene Pact to Provide Diagnostic Suit In U.S.

Albemarle

Landbridge Co LLC

Shareholders of L Brands Inc. ( LB , Financial), Albemarle Corp. ( ALB , Financial) and Bio-Rad Laboratories Inc. ( BIO , Financial) saw the value of their shares increase significantly in recent years, outperforming the S&P 500 Index.

3 Strong Performers That Have Beat the Market

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced a partnership with Seegene, Inc., a global leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease molecular diagnostic products. Under the terms of the agreement, Seegene, based in Seoul, Korea, will provide diagnostic tests for use on Bio-Rad's CFX96™ Dx Real-Ti

Bio-Rad Announces Partnership with Seegene for Molecular Diagnostic Testing Products

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its PREvalence™ ddPCR® SARS-CoV-2 Wastewater Quantification Kit, a sensitive, accurate, and cost-effective tool used to detect SARS-CoV-2 in a community's wastewater. “With wastewater testing becoming more widely adopted, this assay provides the ability for a community to determine if the virus is present day

Bio-Rad Launches Its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit for COVID-19 Wastewater Testing

CVS Health

Gilead Sciences

STAAR Surgical

It is hard to believe, but in just over two weeks the second quarter will come to a close and many investors will be reviewing their portfolios and making changes for the second half of 2021.

Why 4 Jefferies Franchise List Stocks Could Be Big Second-Half Winners

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO, will participate in a Fireside Chat at Jefferies Virtual Healthcare Conference on Wednesday, June 2, at noon (Pacific Time). A link to the live webcast of the presentation will be avail

Bio-Rad to Participate at Jefferies Virtual Healthcare Conference

Logitech

Sturm, Ruger & Company

T. Rowe Price Group

When it comes to picking stocks, most investors go gaga over earnings and pay little attention to a company's financial strength.

Why I Relish Low-Debt Stocks

Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q1 2021 Results - Earnings Call Transcript

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2021. First-quarter 2021 net sales were $726.8 million, an increase of 27.1 percent compared to $571.6 million reported for the first quarter of 2020. On a currency-neutral basis, quarterly sales increased 23.4 percent compared to the same period in 2020. First-quarte

Bio-Rad Reports First-Quarter 2021 Financial Results

Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.

BioRad (BIO) to Report Q1 Earnings: What's in the Cards?

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Rad Laboratories (BIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Bio-Rad comes on an extensive history of share price performance, backed by a robust fundamental underlie.

Bio-Rad: Sartorius Portfolio Inclusion The Key Differentiator

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2021 on Thursday, April 29, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day. To listen, call 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., passcode: 4692298.

Bio-Rad to Report First-Quarter 2021 Financial Results, Thursday, April 29, 2021

KB Financial Group

Winnebago

In my opinion, investors could be interested in the three stocks listed below, as they meet the following criteria:

A Trio of Stocks With a History of Sales and Earnings Growth

Fulgent Genetics

IDEXX Laboratories

We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.

News for Bio-Rad Laboratories Stock (BIO)